Analysis of the reasons why some people do not recommend the use of tilpotide/tilsiparatide (Mufengda)

Tirzepatide (Tirzepatide), as a GIP/GLP-1 dual-target drug, is outstanding in weight loss and improving blood sugar, but not everyone is suitable for use. First of all, it is clearly marked in the clinical instructions that it is not suitable for patients with a previous family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, because animal experiments suggest the potential risk of thyroid-stimulating tumors; although there is no clear evidence in humans, high-risk groups still need to strictly avoid it. In addition, patients with a history of pancreatitis should also be used with caution, because there may be a relationship between GLP-1 drugs and pancreatitis. If there has been an episode of acute pancreatitis in the past, it is not recommended to continue using the same kind of drugs.

Secondly, the use of tilpotide is generally not recommended for some people with sensitive digestive systems, such as those with long-term severe gastroparesis, chronic gastrointestinal motility disorders, or frequent vomiting. This drug increases the feeling of fullness by delaying gastric emptying, which may aggravate existing gastrointestinal symptoms, make nausea, bloating, constipation, or diarrhea more obvious, and even affect the ability to eat daily. For these patients with already weak gastrointestinal function, the benefits brought by drugs are often difficult to offset the potential aggravation of discomfort.

Third, tilpotide has a strong effect in regulating blood sugar, so there is a risk of hypoglycemia for diabetic patients who are taking insulin or sulfonylureas. If the patient's blood sugar control is already low, eating habits are poor, or there is a history of frequent hypoglycemia, the doctor may recommend suspending or reducing the dosage of other anti-diabetic drugs to avoid dangerous hypoglycemic events. In addition, for people with poor renal function or high risk of dehydration, extra caution is needed to avoid inducing fluid imbalance because tilpotide can cause vomiting and loss of appetite.

Finally, it is generally not recommended for pregnant women, lactating women, and those planning pregnancy to use tilpotide because there is currently a lack of sufficient human reproductive safety data, and certain embryotoxicity has also been observed in animal experiments. For women with strong weight management needs, doctors often recommend stopping the drug for a period of time before pregnancy and avoiding use during pregnancy. In addition, adolescents under the age of 18 also lack clinical research data and are not recommended for use. Overall, although tilpotide is effective, whether it is suitable for use needs to be determined by a doctor based on a comprehensive assessment of the disease status, past medical history, and potential risks.

Reference materials:https://www.drugs.com/tirzepatide.html